Gen2 Neuroscience uses proprietary human stem cell platforms and models of genetic forms of dementia to identify and target extracellular, pathogenic forms of tau, with the aim of developing novel drugs to specifically target these tau species.

Gen2 is addressing the hypothesis that dementia is associated with the spreading of distinct species of the microtubule-associated protein tau throughout the brain, due to transfer of specific pathologenic forms of tau between neurons. Gen2’s technologies enable the development of anti-tau therapeutics that specifically target toxic tau, avoiding abundant normal tau species that transfer between healthy neurons. Major benefits of avoiding the majority of healthy, non-toxic tau include increased target engagement, reduced unwanted effects and lower dosing, compared with therapeutics that cannot distinguish among normal and pathogenic tau forms.

Our Science